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ABSTRACT 
Type II Diabetes (T2DB) is one of the worldwide problems characterized by 
ineffective insulin signal transduction as a result of insulin resistance and impaired glucose 
homeostasis. Protein Tyrosine Phosphatase 1B (PTP1B), an enzyme in phosphatase family 
that share a conserved structure in their catalytic domain, is a major regulator of the 
signal transduction. The enzyme functions by dephosphorylation of insulin receptor and 
insulin receptor substrate. Genetic and experimental evidences suggested that the 
enzyme is an attractive drug target for Type II Diabetes. Many research groups have 
attempted to develop inhibitors of PTP1B. However, none of them has made it to the drug 
market due to inefficiency to function. Development of PTP1B inhibitor has proven rather 
difficult owing to three main challenges, i.e. potency, selectivity, and cell permeability. 
Here, we report a novel strategy that possibly overcomes those main challenges. I 
describe the development of potential exo-affinity labeling agents targeting PTP1B 
function, investigation of potency of the agents which were are reported as IC50 values, 
as well as kinetics study of those compounds against the enzyme.
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Chapter 1  
Type II Diabetes, PTP1B, & Current Inhibitors of 
PTP1B 
 
1.1) Introduction: Type II Diabetes, a nationwide problem. 
Diabetes is a metabolic disease resulting from either failure of insulin production 
by β-cells in the pancreas or impaired insulin sensitivity.1 Diabetes is a national health 
problem with data from the 2011 National Diabetes Fact Sheet showing that 25.8 million 
children and adults in the United States—8.3% of the population—have the disease.2  
Moreover, diabetes is linked to many other health issues. In 2004, for example, 68% and 
16% of people in the age of 65 or older died from diabetes-related heart disease and 
diabetes-related stroke, respectively. Furthermore, diabetes also leads to high blood 
pressure, blindness, kidney disease, nervous system disease, and amputation. In 2007, 
diabetes was the seventh leading cause of death, accounting for 231,404 deaths.  
Additionally, cost of diagnosed diabetes in the US was $245 billions in 2012. These show 
that diabetes is a serious nation’s health problem and new medical treatments are 
needed. 
Diabetes is divided into two major types. Type 1 diabetes (T1DB), so-called insulin-
dependent, is commonly found in children and young adults and is characterized by 
failure to produce insulin due to the body’s immune destruction of pancreatic β-cells.3 
People with T1DB need insulin from external sources such as insulin injection or pump. 
The other type of diabetes is type 2 diabetes (T2DB) which is called non–insulin-
dependent diabetes. T2DB is the most common and accounts for about 90% to 95% of all 
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diagnosed cases of diabetes.4 Unlike T1DB, this type of diabetes is characterized by insulin 
resistance and impaired glucose tolerance (IGT).4,5 In other words, cells of people with 
T2DB do not response properly to insulin, a peptide hormone that normally signals 
glucose uptake. Consequently, the glucose in blood stream is accumulated, leading to 
high blood glucose (hyperglycemia) and at this point glucose becomes toxic 
(glucotoxicity). Meanwhile, pancreatic β-cells is in stress due to producing more insulin to 
compensate for insulin resistant. Increasing this stress overtime, IGT evolves to T2DB.6,7 
T2DB was previously observed primarily in adult populations, associated with a sedentary 
lifestyle, but has now also become a medical problem in children.8, 9 Increase in these 
driving factors of T2DB as well as  inadequate and ineffective current therapeutic methods 
have caused the disease to become an epidemic.9 Therefore, a new approach to the cure 
and understanding the mechanism associated with the disease are needed. 
 
1.2) Insulin signaling transduction and Protein Tyrosine Phosphatases 
(PTPs) 
Insulin is a peptide hormone produced by β-cells of pancreas. The hormone 
functions by controlling carbohydrate and fat metabolism in peripheral (liver, muscle, fat) 
and central (hypothalamus) tissues7 through the mechanism called insulin signaling 
transduction. 
Insulin signaling transduction begins with insulin-induced autophosphorylation at 
tyrosine residues of the Insulin Receptor (IR) (figure 1.1).10 This activation results in 
recruitment and chain phosphorylation of Insulin Receptor Substrates (IRS) and 
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downstream substrates such as phosphatidylinositol 3-kinase (PI3K), protein kinase B and 
(PKB; also known as AKT). The activation of IR also leads to relocation of glucose 
transporter 4 (GLUT4) which transports glucose into the cell and subsequently decreases 
concentration of blood glucose.11, 12  This process is negatively controlled by protein 
tyrosine phosphatases (PTPs).13 Studies have shown that several PTPs, i.e. receptor 
protein tyrosine phosphatase-α (rPTP-α), leukocyte antigen-related tyrosinephosphatase 
(LAR), SH2-domain-containing phosphotyrosine phosphatase (SHP2), and protein tyrosine 
phosphatase 1B (PTP1B) modulate the insulin signal transduction.13-15 PTP1B is the major 
contributor in modulating insulin signal transduction.15  Therefore, inhibition of PTP1B 
may offer a new therapeutic method of T2DB. 
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Figure 1.1 Insulin Signaling Transduction scheme. The signaling pathway is negatively regulated by PTP1B. 
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1.3) Evidences link PTP1B to T2DB 
There is evidence showing that PTP1B negatively regulates the insulin signaling 
pathway both in vitro and in vivo. For instance, two studies conducted by Chen et al. and 
Venable et al. showed that when PTP1B in rat primary adipose tissue was over expressed, 
insulin-sensitivity of GLUT4 translocation was decrease.16, 17 Similarly, the effect of insulin 
on PTP1B activity is also studied by two independent groups. Mahadev et. al. discovered 
that insulin diminished PTP1B activity in vitro by promoting the production of hydrogen 
peroxide (H2O2),18 an active-site directed inactivator of PTP1B. Tao et. al. revealed that 
PTP1B activity was reversibly regulated by insulin through tyrosine phosphorylation in 
vivo. 19  There are not only studies that associate PTP1B activity with insulin sensitivity, 
but also there are studies showing that PTP1B could be a potential drug target of T2DB. 
Firstly, studied in 1999 and 2000, PTP1B-deficient mice showed increased insulin 
sensitivity and resistance to weight gain on a high-fat diet.19, 20 Secondly, an evidence from 
crossing the PTP1B-deficient mouse onto an ob/ob (genetically severe obesity with 
hyperphagia and diabetes) background revealed that resting metabolic rate was 
enhanced as well as adipose (fat) tissue was lowered resulting in reduced weight gain.21 
Lastly, in 2002, when ob/ob mice was treated with PTP1B antisense oligonucleotide, 
reduced blood glucose levels and increased insulin sensitivity in fat and lever cell were 
observed.22 These evidences show that PTP1B inhibition could serve as a promising drug 
target for treatment of T2DB. 
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1.4) Structure of PTP1B 
Because PTP1B has been validated as a drug target of T2DB, structural and 
functional insight of PTP1B might be used to develop a new therapeutic approach. 
Following  to the data connecting PTP1B and T2DB mentioned above, there have been 
many studies related to PTPs. 107 enzymes in PTP super family were identified as a result 
of completion of the human genome sequences in 2001.23 PTPs were divided into four 
subfamily, i.e. class I, class II, class III, and class IV.24 Class I is the largest and consists of 
99 members which are compose of 61 dual-specific phosphatases and 38 classical PTPs. 
The latter PTPs comprised of 21 receptor PTPs and 17 non-receptor PTPs. PTP1B is a 
cysteine-based non-receptor PTP in this class.  
PTP1B is composed of 435 amino acid residues, of which the residue 30–278 are 
the catalytic domain, 35 carboxy-terminal residues are proline rich which facilitate the 
interaction of the enzyme to the endoplasmic reticulum. Catalytic loop of the enzyme 
contains an active site, the WPD (Trp179, Pro180, and Asp181) loop and the secondary 
aryl-phosphate binding site which is catalytically inactive, and provides weaker binding 
interactions compared with the primary site.25 Additionally, YRD (Tyr46, Arg47, and 
Asp48) motif and the gateway residue Gly259 are located in the catalytic domain, 
controlling phosphatase substrate selectivity. The active site consists of residue 214–
221(His, Cys, Ser, Ala, Gly, Ile, Gly, and Arg) with Cys215 as a catalytic residue, as well as 
the residues residing on the catalytic cleft, Asp181, Phe182, Tyr46, Val49, Lys120 and 
Gln262 which contribute to catalysis and substrate recognition. The depth of the catalytic 
site is 8–9 Å. This depth defies the substrate selectivity as serine and threonine substrate 
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are not long enough to allow nucleophilic attack by Cys215. The WPD loop (Trp179, 
Phe180, Asp181) is also account for enzymatic catalysis by undergoing conformational 
change - open and closed conformations - upon substrate binding.26 When binding to a 
phosphotyrosine substrate (pY), WPD loop moves up to 12 Å forming hydrophobic 
interactions with the phenyl ring of pY as well as Asp181 and Arg221 simultaneously 
relocate to provide general acid catalysis and optimized salt bridge interaction with the 
phosphate group of the substrate, respectively. The conformational change allows Cys215 
to position for nucleophilic attack on the substrate phosphorous atom promoting 
dephosphorylation catalysis. 
 
1.5) Dephosphorylation Mechanism of PTP1B 
The general mechanism of PTP1B in dephosphorylation its phosphotyrosine 
substrate (pY) is described below (Scheme 1.1). The dianionic pY is recognized and bind 
to the positively charged active site of PTP1B that composes of eight amino acids residues 
His214-Arg221. The active site containing a nucleophilic Cys215 residue is unexposed to 
solvent. Stabilization within the active site causes Cys215 to possess an unusual decreased 
pKa value of 4.5-6 approximately compared to normal protein cysteines that have pKa 
value of about 8.27 When binding to pY, Asp181 acting as a general acid moves closer onto 
the active site and facilitates nucleophilic attack by Cys215 at the phosphorous center of 
pY. The dephosphorylated substrate then diffuses off the active site and a water molecule 
subsequently undergoes nucleophilic attack of phospho-cysteine intermediate to 
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regenerate the Cys215 in the active site. This process is catalyzed by Asp181 as a general 
base catalyst. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.1 Dephosphorylation Mechanism of PTP1B.28  
 
1.6) Current PTP1B inhibitors and their inadequate inhibitory activity 
There had been efforts to develop competitive inhibitors of PTP1B. However, the 
development was found to be rather difficult and three main challenges were addressed, 
i.e. potency/affinity, selectivity, and cell permeability. 
Typical PTP1B inhibitors gained potency/affinity by binding two sites, i.e. the 
active site pocket and a site proximal to the active site, on the enzyme target (figure 1.2). 
The inhibitors bound to the active site by mimicking the binding manner of pY and 
simultaneously interacted with the proximal site to the active site. This binding mode, 
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called “Dual Binding,” allowed the inhibitors to bind to PTP1B more tightly than pY and 
gained higher affinity which led to greater potency. 
Selectivity to PTP1B over PTPs still remained challenging. Although some of these 
inhibitors exhibited high affinity to the enzyme active site, they could not differentiate 
between the active site of PTP1B and the active sites of PTPs, resulting in promiscuous 
inhibition, especially the inhibition of T-Cell PTP (TC-PTP), the highly homologous 
(identical active site, WPD loop, YRD loop, and 74% sequence identity in the catalytic 
domain) to PTP1B. The consequence of inhibiting TC-PTP was unclear but there was a 
study showing that TC-PTP-deficient mice died within 3-5 weeks.25 Therefore, good 
selectivity to PTP1B was one of the desired property of PTP1B inhibitor. 
Unfortunately, few inhibitors that possessed high potency and good selectivity 
prevented them from penetrating cell membranes. Examples of current PTP1B inhibitors 
are provided below. 
  
 
 
Figure 1.2 Binding mode of typical dual binding inhibitor. 
Difluoromethyl Phosphonate (DFMP) Phosphotyrosine Isosteres which are the 
first major pY mimetic discovered by Burke et. al. in 1994 have been developed for 
decades.29 One of the most potent PTP1B inhibitor 1 to date was reported by Zhang et. 
al. (figure 1.3). Utilizing dual binding strategy with the active site and a secondary aryl-
phosphate binding site as well as charge-charge interactions and interactions of difluorine 
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atoms to several enzyme residues contributed to high potency with Ki (dissociation 
constant) of 2.4 nM.30 Regardless of the high potency, the inhibitor was only 10-fold 
selective to PTP1B over closely homologous TC-PTP. Furthermore, because of the bis-
anionic property, the inhibitor exhibited poor cell permeability and low oral 
bioavailability.31 
Similarly, Merck Frosst developed a dual-binding benzotriazo DFMP 2 that 
possessed great potency with IC50 value of 5 nM32 (IC50 is the inhibitor concentration 
where the enzyme activity is decreased by 50%, figure 1.3). Co-crystal structure of 2 and 
PTP1B showed that the inhibitor bound to the active site and another secondary 
phosphotyrosine binding site.22,33 However, the compound achieved only 7-fold 
selectivity over TC-PTP and exhibited undesirable pharmacokinetics due to bis-anionic 
nature.        
 
 
  
 
Figure 1.3 Difluoromethyl Phosphate 1 developed by Zhang et. al. and Benzotriazo DFMP 2 developed by 
Merck Frosst. 
 
Mono and Dicarboxylic Acid Phosphotyrosine Isosteres The efforts to improve cell 
permeability, by reducing the negative charges, resulted in replacing DFMP scaffold with 
one or more carboxylic acid groups. Several novel carboxylic acid-containing inhibitors 3-
533-35 achieved good to excellent inhibitory potency (5-1000nM) with moderate selectivity 
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over TCPTP (<20-fold) (figure 1.4). These compounds, however, still suffered from poor 
cell membrane penetration.33-35 
 
 
 
 
 
 
Figure 1.4 Carboxylic acid-containing PTP1B inhibitors 3-5 developed by Abbott. 
 
  
 
 
 
Figure 1.5 Tyrosine Acid 6 and Thiophene diacid 7 developed by The Institutes for Pharmaceutical Discovery 
and Wyeth respectively. 
 
The Institutes for Pharmaceutical Discovery and Wyeth also published highly 
potent inhibitors of PTP1B 6 (IC50 = 16 nM)36 and 7 (Ki = 5 nM)37, respectively (figure 1.5). 
Nonetheless, due to extremely hydrophobic and high molecular weight (MW), 6 fell off 
the range of drug-like properties according to Lipinski’s rule of 5.38 Likewise, although 7 
demonstrated excellent potency, it lacked of selectivity and cellular activity.  
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Figure 1.6 PTP1B inhibitors containing TDZ or IZD 8-11. 
Heterocyclic Phosphotyrosine Isosteres Another class of PTP1B inhibitors 
contained a diffusely anionic heterocycles, 1,2,5-thiadiazolidin-3-one-1,1-dioxides 
(TDZs)39, 40, 41, 42-44 or (S)-isothiazolidinones ((S)-IZD) 8-11 (figure 1.6).45, 46, 47,48 This class 
was an attempt to reduce di-anionic charge found in DFMP and carboxylic acid-containing 
inhibitors, in order to improve cell membrane penetration. Based on parallel artificial 
membrane permeability assay (PAMPA) data, the cell permeability trend was TDZs (0.19-
3.54 nm/s) > monoacid (0.22 nm/s) > diacid (0.00 nm/s).46 Furthermore, regarding low 
molecular mass, these inhibitors were also in the range of drug-like properties.46 
Owing to the advantage of these heterocyclic compounds concerning cell 
permeability, TDZ is the pY isostere (pYi) of choice that we employ in our work. 
 
1.7) Growing Interest of Covalent Drugs 
Regarding inadequate efficiency of the current PTP1B inhibitors, a new class of the 
inhibitor which possesses the desired potency, selectivity, and cell permeability as well as 
drug-like properties was needed. Intriguingly, there was growing interest in another type 
of inhibitor, called covalent inhibitors.49 This type of inhibitor, or so-called inactivator or 
irreversible inhibitor, bound to their targets similar to that of reversible inhibitor, but they 
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were capable of forming a covalent bond to the targets, resulting in irreversible inhibition 
or inactivation of the target activity. For example, In 1998, Fry et al. reported an 
irreversible inactivator of epidermal growth factor receptor (EGFR).50 Due to covalently 
modification, the potency of the inactivator increased by 5-fold in vivo. In 2005, Taunton 
and team reported fluoromethylketone-pa (fmk-pa) that specifically formed covalent 
bond with p90 ribosomal protein S6 kinase 1 (RSK1) and p90 ribosomal protein S6 kinase 
(RSK2) in mammalian cells.51 The cellular potency was also increased by 5-fold compared 
to that of reversible inhibitor fmk. In 2007, Cravatt’s group52 designed covalent inhibitors 
which were highly selective to fatty acid amide hydrolase (FAAH), while non-covalent 
inhibitors modified multiple serine hydrolases. These studies proved that covalent 
inhibitor achieved high potency and selectivity as the main challenges in development of 
PTP1B inhibitor. 
Furthermore, there were evidences showing that covalent modification could 
improve not only potency and selectivity of this type of inhibitor, but also rate of reaction 
via proximal acceleration. Proximal acceleration occurred when two reactive groups were 
held closely to each other and in the right conformation. The proximity and the 
complementary angle facilitated bond formation and thus enhanced the rate of 
reaction.53 For instance, Belshaw54 et. al. compared efficiency in inhibition of an 
engineered receptor-ligand with and without complementary reactive groups to a 
reactive cysteine residue of a receptor. Within 16 h, the former reduced the activity of 
the receptor to 0%, while the activity inhibited by the latter remained at 76%. Meares and 
co-worker developed ligands containing electrophilic groups for mutant antibody (S95C 
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and N96C) fab fragment.55 With covalent modification, 50% of the mutant fab containing 
a complementary group to that of the ligands was bound in 10 min, whereas the same 
amount of mutant fab without the complementary group took 50-100 min at the same 
condition.  Wells and team reported a proximity-accelerated reaction, called “Tethering 
Strategy” where a nucleophilic cysteine residue and an electrophilc disulfide were 
introduced into thymidylate synthase and a ligand (called tethering ligand), respectively.56 
Due to the complementary groups, Ki (dissociation constant) of the tethering ligand was 
found to be improved by 3000-fold, comparing to a ligand without disulfide (called 
untethering ligand). Additionally, Gartner and Liu reported the enhanced rate of DNA-
double stranded synthesis through proximity acceleration when a DNA template was 
modified with an electrophilic group that non-complementary and complementary to a 
nucleophilic thiol group on DNA oligonucleotide.57 However, no reaction occured when 
the electrophilic group was non-complementary to the thiol group. Mentioned earlier, an 
irreversible and selective inhibitor of EGFR was made by Fry and team.50 With the 
proximity-acceleration reaction, the irreversible inhibitor containing an electrophilic 
acrylamide took 1 min to reach 100% inhibition by labeling Cys773 of EGFR, whereas the 
reversible inhibitor did not showed inhibition even extending time to 8 h. As far as the 
evidences above were concerned, the covalent modification was proved to be a promising 
key to achieve potency and selectivity of a novel class of PTP1B inhibitor. 
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1.8) Goal of Thesis 
T2DB has become a serious national problem in the past decades and the current 
treatments of T2DB are ineffective. PTP1B was proved to be a potential drug target to 
treat this disease, but the development of new PTP1B inhibitors with the desired 
inhibitory properties (potency/affinity, selectivity, and cell permeability) was rather 
difficult and remained challenging. This leads to the need in a novel strategy to combat 
T2DB. 
Concomitantly, there was growing attention in development of covalent drug 
industry due to promising properties of the drugs that could provide greater inhibitory 
efficiency over non-covalent drug, i.e. improved potency, higher selectivity, and 
accelerated rate of inhibitory reaction. Therefore, utilizing covalent binding strategy 
became attractive to include in our strategy aiming PTP1B inhibition. 
The goal of this thesis is to develop a new class of PTP1B inhibitors that provide 
the desired inhibitory efficiency and could serve as a new covalent drug of T2DB as well 
as to study inhibitory kinetics of the inhibitors for future optimization. 
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Chapter 2 
Exo-affinity Labeling Agents & PTP1B Inactivation 
 
In recent decades, pharmaceutical companies and industries have developed 
small molecules to regulate PTP1B activity, aiming to treat T2DB. None of them, however, 
have made it to the clinic.1 Balancing potency, selectivity, and cell permeability are the 
main reasons why discovery of PTP1B inhibitor still remain challenging. The active site of 
PTP1B is highly cationic and favor binding to complementary multiple negatively charged 
molecules.2-3 Hence, Multiple negatively charged PTP1B inhibitor, for example DFMP 1 
and 2 (chapter 1, page 8) exhibited high affinity binding to the active site pocket. 
Unfortunately, the charges prevented the molecules to enter the cell, thus disqualified 
the molecules as drug candidates. Lastly, the active site structure of PTPs to where most 
of PTP1B inhibitors bound was very well conserved. This presages the difficulty to design 
a small molecule that selectively inhibit PTP1B over other PTPs, especially TCPTP, the 
highest identical to PTP1B in catalytic domain. In this chapter, we introduced a radically 
different strategy to regulate PTP1 activity and promisingly provide the desired 
properties. 
 
2.1) Exo-affinity Labeling Agent, a novel covalent inhibitor of PTP1B 
An affinity labeling agent is an irreversible inhibitor,4 or an inactivator, that 
covalent modifies a residue located inside (endo-affinity labeling) or outside (exo-affinity 
labeling) the catalytic site of the enzyme. There are two steps involved in the inactivation 
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(Scheme 2.1). The first step is a fast (usually occurs within micro- or millisecond), 
reversible formation of an enzyme-agent complex 𝐸 ∙ 𝐼. During this step, several amino 
acid residues on the enzyme active site form non-covalent interactions to the affinity 
labeling agent with the rate k1. Simultaneously, the complex can fall back to a free enzyme 
molecule and a free affinity labeling agent molecule with the rate k-1. These two processes 
result in equilibrium with a dissociation constant (KI) which is defined by k-1/k1. The non-
covalent binding step is followed by covalent modification where two reactive and 
complementary groups on the enzyme and the agent, typically a nucleophile on the 
enzyme and an electrophile on the affinity labeling agent, form a covalent bond to give 
an enzyme-inactivator adduct 𝐸 − 𝐼. This process proceeds with the pseudo-first-order 
rate constant (kinact). Since the covalent bond is formed, the affinity labeling agent remains 
at the active site irreversibly and prevented enzyme’s activity by blocking the interaction 
with its substrate. In this thesis, we developed a family of exo-affinity labeling agent of 
PTP1B. The detail will be discussed below. 
 
 
Scheme 2.1 Inactivation of an enzyme by an affinity labeling agent. 
 
 
2.2) Advantages of exo-affinity labeling agents over reversible inhibitors. 
 
We chose to explore exo-affinity labeling agents because of several advantages 
over the current PTP1B inhibitors, i.e. irreversible inhibition, higher inhibitory efficiency, 
and potentially greater specificity. 
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Firstly, the enzyme inhibition by the exo-affinity labeling agents is irreversible but 
the inhibition by the current inhibitors is reversible. According to scheme 2.1, the exo-
affinity labeling agent binds to the target enzyme in two steps, non-covalent interactions 
with equilibrium constant KI followed by covalent bond formation with the rate constant 
kinact. Upon the second step, the agents permanently bind to the target (infinite affinity), 
blocking the enzyme activity. Unlike permanent inhibition, the inhibition by current 
inhibitors is transient because they form only reversible interactions to the target 
enzyme. Therefore, as far as the covalent bond is concerned, the exo-affinity labeling 
agents provide irreversible inhibition or infinite affinity which will results in higher 
potency comparing to the current inhibitors. 
 
 
 
 
Figure 2.1 Irreversible inhibition versus transient inhibition. 
 
Secondly, the affinity labeling agents have the potential for higher inhibitory 
efficiency, i.e. effective inhibition at high concentration of substrate, longer duration of 
inhibition, and lower required effective dose. First, at high concentration of an enzyme 
substrate, a competition for the enzyme active site between a reversible inhibitor and the 
+ 
Exo-affinity Labeling Agent Inactivated PTP1B 
(Irreversible Inhibition) 
Dual Binding Inhibitors Inhibited PTP1B 
(Reversible Inhibition) 
+ 
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substrate occurs, interrupting the equilibrium of the enzyme and the inhibitor. This 
interruption facilitates the rate of 𝐸 ∙ 𝐼 complex breaking down (k-1) and causes the 
inhibition to be deficient. On the contrary, the exo-affinity labeling agents can bind to the 
target enzyme with the covalent bond. Once the permanent bond takes place, the exo-
affinity labeling agents and the enzyme cannot fall back to their free forms. Thus, the 
competition might have no or little effect on the irreversible inhibition (Figure 2.2). 
Second, similar to the advantage of covalent drugs over non-covalent drugs, the exo-
affinity labeling agents can also provide longer duration of inactivation. Once the covalent 
bond is formed, the activity of the enzyme will not be recovered until a new enzyme 
molecule is synthesized, resulting in longer inhibitory effect. Third, as long as the synthesis 
of the new enzyme was not too fast, another portion of the inactivator (or new dose of 
the drug) is not necessary and less dose is required to achieve a certain inhibitory effect, 
comparing to reversible inhibitors. Moreover, since less dose is needed, the possibility of 
possible adverse reactions which are highly concerned by many drug companies are also 
reduced.5 Taking these advantages to account, the affinity labeling agent could provide 
higher inhibitory efficiency than the current inhibitors. 
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Figure 2.2 Inactivation by the exo-affinity labeling agent (top) and inhibition by a dual binding inhibitor 
(bottom). The exo-affinity labeling agent bound to PTP1B with a covalent bond. This irreversible interaction 
was not affected by the competition with the substrate (top). Dual binding inhibitors bound to PTP1B with 
non-covalent interactions. This reversible interaction was affected by competition with the substrate 
(bottom). 
 
Lastly, greater selectivity over PTPs and common nucleophiles in physiological 
media can be achieved by the affinity labeling agents. There are two factors that 
contribute to the selectivity of the inactivators, i.e. proximity-accelerated reaction and 
targeting a distinct reactive residue. As mentioned earlier, the affinity labeling agents bind 
to the enzyme active site with fast and reversible non-covalent interactions, subsequently 
an irreversible  covalent bond formation at a proximal residue on the enzyme surface. 
Upon the non-covalent binding step, one part of the agent is in the active site and the 
other part freely swing in/outside (depends on the structure) the active site pocket. At 
this point the active moiety on the agents (typically an electrophile) and a target residue 
on the enzyme (typically a nucleophile) are brought up more closely. Holding two reactive 
groups closer and in the right conformation for the reaction is similar to increasing the 
concentration of both groups, facilitating the rate of reaction.  The concentration of the 
+ 
Exo-affinity Labeling Agent Inactivated PTP1B 
(The extent of Inhibition is not 
affected by amount of pY) 
Dual Binding Inhibitors Inhibited PTP1B 
(The extent of Inhibition affected 
by amount of pY) 
+ 
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reactant or catalytic group required to cause the intermolecular reaction to proceed at 
the observed rate of the intramolecular reaction was called Effective Molarity (EM), 
defined by Kirby in 1980.6,7 Regarding the proximal acceleration, the EM of 𝐸 ∙ 𝐼 complex 
increases, the rate of inactivation, which is dependent directly on the concentration of 
𝐸 ∙ 𝐼 complex, also increases (Figure 2.3). In contrast, the common nucleophiles and some 
enzymes in PTP family, who do not possess an active site or whose active sites are not 
complementary to the structure of the affinity labeling agent, will not be capable of 
binding to the agent with non-covalent interactions. Thus, a reactive group on those 
nucleophile or enzymes and the reactive group on the agent cannot be brought up more 
closely and the rate of inactivation will not be improved by EM. Therefore the rate will be 
relatively slower than the rate of inactivation between the target enzyme and the agent. 
(Figure 2.4a, b, c) 
 
 
 
 
Figure 2.3 Proximity-accelerated reaction of E-L-pYi.  
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a)  
 
 
b) 
 
 
c) 
 
 
d) 
 
 
Figure 2.4 Binding mode of an exo-affinity labeling agent to a) the target enzyme, b) other enzymes whose 
active sites are not complementary to the structure of the affinity labeling agent, c) common nucleophiles 
in physiological media and d) homologous enzyme without the reactive group or with the reactive group 
not located in the proper distance. 
 
The other factor that contribute to greater selectivity over typical inhibitors is 
targeting a distinct reactive residue on the enzyme surface. Since the affinity labeling 
agents form covalent bond with a reactive amino acid in the active site or a certain 
distance away from the active site, if this amino acid is non-conserved (not found in other 
enzymes but PTP1B), the covalent bond formed will be exclusive to PTP1B. On the other 
hand, other PTPs that do not possess the reactive group or contain the reactive group but 
not the proper distance from the active site will not be able to form the covalent bond 
with the affinity labeling agents and the inhibition by the agents will be reversible like that 
+ 
Exo-affinity 
Labeling Agent 
Inactivated PTP1B 
(Irreversible Inhibition) 
Inhibited enzyme 
(Reversible Inhibition) 
+ 
Common 
Nucleophiles 
+ 
Homologous 
Enzymes 
+ 
Transient 
Inactivation 
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of common inhibitors (Figure 2.4d). Therefore, the affinity labeling agents could be more 
selective than typical inhibitors due to proximity-accelerated reaction and targeting a 
distinct reactive residue. 
With these advantages, we decided to develop exo-affinity labeling agents for 
PTP1B. The design of the agents will be described below. 
 
2.3) Design of Exo-Affinity Labeling Agent of PTP1B 
Our exo-affinity labeling (E-L-pYi) design comprised of three parts; a 
phosphotyrosine isostere (pYi), a linker (L), and an electrophile (E). (Figure 2.5) 
 
 
 
Figure 2.5 Design of the exo-affinity labeling agent, E-L-pYi 
 
Phosphotyrosine Isostere (pYi) selection Current inhibitors, e.g. DFMP and 
carboxylic acid inhibitors were highly potent, but suffered from poor cell permeability and 
low cellular activity due to bis-anionic property. To overcome the cell permeability issue, 
study and synthesis of a minimal charged compound that was capable of mimicking pY 
substrate was undertaken. In 2005, Black and co-workers reported o-methoxy TDZ 8 with 
improved IC50 = 2.5 μM.8 The inhibitor had only one negative charge (N atom at position 
2 has pKa of 2 approximately, measured by Parsons, Z.D. my colleague), low molecular 
weight, and the structure was in the range of drug-like compound, offering an opportunity 
Electrophile 
Linker 
Phosphotyrosine Isostere 
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to modify its structure as the ideal covalent drug of PTP1B. Moreover, revealed by X-ray 
structure, the compound occupied the active site pocket with the phenyl ring pointing 
toward two nucleophilic amino acid residues, i.e. Cys32 and Asp48 with the distance of 
14.2 Ȧ and 5.2 Ȧ (measuring from the end p-carbon), respectively (Figure 2.6). This offered 
an opportunity to develop a selective exo-affinity labeling agent by targeting residue 
proximal to the active site of the enzyme. 
 
 
 
 
 
 
 
 
Figure 2.6 Pymol co-structure of 8 and PTP1B. The distances from p-carbon at the end of 8 to Asp48 and 
Cys32 are 5.2 Ȧ and 14.2 Ȧ, respectively. 
 
Electrophile I selection As far as the advantages of covalent inhibitors over non-
covalent inhibitors were concerned, adding an electrophile moiety targeting a 
nucleophilic residue on the exo-affinity labeling agent could improve its potency and 
selectivity if the target amino acid on PTP1B surface is non-conserved. Based on crystal 
structure of PTP1B from protein data bank (the structure in PDB entry 2HNP9 is used as a 
reference), there are several reactive amino acids proximal to the PTP1B active site, i.e. 
Ser118, Tyr46, Asp48, Glu115, and Ser32, and Cys32. (Figure 2.7) Targeting these amino 
acids could be the key to selectivity to PTP1B over other PTPs.  
                    Asp48 
 
Cys32 
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The electrophile of choice needs to be complementary or susceptible to the target 
residue on the surface of PTP1B and also inert toward common cellular nucleophiles, such 
as glutathione, albumin. Thioester and α-halo carbonyl groups have been reported to be 
reactive toward several nucleophilic amino acids,10 but tolerate biological nucleophiles. 
11, 12 In this thesis, the thioesters are incorporated into our agent molecules.  
 
 
 
 
 
 
 
 
Figure 2.7 Positions of nucleophilic residues in PTP1B proximal to the active site. 
Linker Selection (L) Characteristics of an ideal linker comprised of availability of 
functional groups, water solubility, and flexibility of dimensions.13 However, in the first 
generation of our exo-affinity agent, we utilized several C-C bonds to link the 
electrophile and pYi moiety together. 
 
2.4) Synthetic Route to First Generation of E-L-pYi 
TDZ as the pYi was obtained by Black’s method. (Scheme 2.2)8 This route was first 
brought into our lab by my colleague, Hillebrand, R. The synthetic route started with 
brominated anilines 12 undergoing alkylation with methyl α-bromoacetate to yield an 
Cys32 
Asp48 
Tyr46 
Glu115 
Ser118 
PTP1B 
Active Site 
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adduct 13, followed by sulfonylation of Boc-protected chlorosulfonamide. The resulting 
boc-protected product 14 was deprotected with TFA and cyclized by NaH to form mono-
aryl TDZs 16. Another phenyl ring carrying various functional groups was added to the 
mono-aryl TDZs 16 via Suzuki coupling, giving bi-aryl TDZ derivatives 17-18. Finally, BOP 
((Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate) was used 
to couple biphenyl TDZ bearing a carboxylic group 18 with  different nucleophiles to 
access the first generation of E-L-pYi. (Scheme 2.3) 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2 Synthesis of bi-aryl TDZ by Black’s method.8 (17a and all OMe analogs were synthesized by my 
colleague Ruddraraju, K. V. R.) 
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Scheme 2.3 Synthesis of E-L-pYi. Variety of functional groups offers different reactivity of the electrophile 
part which targets a reactive groups on the enzyme surface. (19a family was synthesized by my colleague 
Ruddraraju, K. V. R.) 
 
2.5) IC50 Determination for compound 8, 19-21 
Potency of an inhibitor is typically measured by determining an IC50 value, the 
concentration of an inhibitor where 50% of target activity was inhibited under some 
specified conditions. The IC50 value of a given inhibitor against its target is obtained by 
examining an effect of different inhibitor concentrations on the target activity and 
plotting the activity versus the concentrations. In this thesis, we employed phosphatase 
assays using p-nitrophenyl phosphate (pNPP) which was dephosphorylated by an active 
PTP1B affording p-nitrophenolate (λmax = 410 nm, Scheme 2.4) to evaluate PTP1B activity 
on different concentrations of our first generation of E-L-pYi. Plotting PTP1B activity 
versus the concentrations and fitting the data to does response equation (Scheme 2.5a) 
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gave IC50 values of each compound at the concentration that gave 50% activity. (Figure 
2.8a, b, c and Table 2.1) 
 
 
 
 
Scheme 2.4 Reaction of pNPP and PTP1B yielding p-nitrophenoxide (λmax = 410 nm). 
a) 𝑦 = 𝑚𝑖𝑛 +
(𝑚𝑎𝑥−𝑚𝑖𝑛)
1+10[(𝑙𝑜𝑔𝐼𝐶50−log[𝑥])(𝑛𝐻)]
 
b) 𝐾𝑖 =
𝐼𝐶50
1+
[𝑆]
𝐾𝑚
 
Scheme 2.5 a) Dose-Response Equation, where min is minimum enzyme activity, max is maximum enzyme 
activity, IC50 is concentration of an inhibitor where 50% of its target activity is inhibited, [x] is the inhibitor 
concentration, and nH is Hill’s coefficient. b) Cheng-Prusoff equation, where KI is the binding affinity of the 
inhibitor, [S] is fixed substrate concentration and Km is the concentration of substrate at which enzyme 
activity is at half maximal (Km = 0.4 mM pNPP8). 
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a) 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
  
c)  
 
 
 
 
 
 
 
Figure 2.8 Plots of % PTP1B Activity versus concentration of a) Me/Ph Thioester TDZ 19a and b) Me/Bn 
Thioester TDZ 20 and c) Me/Ph Amide TDZ 21. IC50 with error bars (from ≥5 experiment) of the compounds 
were 124±12 µM, 270±36 µM, and 244±43 µM, respectively. 
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a triplicate experiments (n ≥ 3) 
b duplicate experiments (n = 2) 
c High Salt condition: 50 mM Tris, 50 mM Bis-Tris, 50 mM DTPA, 80 mM NaOAc, 100 µM DTT, 0.05%v/v 
Tween80, 2 mM pNPP, room temperature, 24 nM PTP1B. 
d Low Salt condition: 2 mM EDTA, 50 mM Bis-Tris, 5 mM DTT, 0.05%v/v Tween80, 0.4 mM pNPP, room 
temperature, 48 nM PTP1B. 
e Low Salt condition: 2 mM EDTA, 50 mM Bis-Tris, 5 mM DTT, 0.05%v/v Tween80, 0.4 mM pNPP, room 
temperature, 72 nM PTP1B. 
f Estimated KI values of 19a, 20, and 21 were obtained from their IC50 values (condition in e) using Cheng-
Prusoff equation (Scheme 2.5b) 
g Plot %Enzyme Activity vs TDZ concentration was extrapolated to IC50 value by curve fitting to does 
response equation (Scheme 2.5a) 
 
Table 2.1 IC50 values in 4% and 20% DMSO, and low and high salt condition. 
As mentioned earlier that E-L-pYi was designed to bind to PTP1B at its active site 
pocket with TDZ moiety. Thus, the compound possessed a certain affinity which was 
measured by dissociation constant (KI). However, IC50 value was typically reported as a 
measurement of affinity of a giving inhibitor instead. Although IC50 was not a direct 
measurement of KI, both values related by the Cheng-Prusoff equation.14 (Scheme 2.5b) 
Using the equation, estimated KI values of 19a, 20, and 21 were obtained. (Table 2.1) 
According to the IC50 values, we discovered that an ionic strength of a buffer (Salt 
effect) and an amount of DMSO (DMSO effect) had an effect on the interaction between 
the enzyme and E-L-pYi. Ionic strength of a buffer is typically referred to salt 
concentration. Salt is capable of screening charge-charge interaction between the 
TDZ 
IC50 (µM) 
Estimated KI 
(µM)f 
20%DMSO 4%DMSO 
High Saltc Low Saltd Low Saltd Low Salte 
17 >300 2167.1g 283.0 - - 
8 65.3 15.2±1.7a 4.3 - - 
19a >300 1100.1g 114.7±6.4b 124.4±12.3a 62.2 
19b 182.8 47.6 10.3 - - 
20 >300 631.0 - 270.2±36.1a 135.1 
21 >400 1349.0 g 216.3 243.9±43.0a 121.9 
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enzyme and the inhibitor resulting in weaker binding. In other words, if the inhibitor binds 
to its target via charge-charge interactions, high concentration of salt, or high ionic 
strength buffer, is expected to decrease binding affinity of the compound and increase 
IC50 value. TDZ moiety contained acidic N-H group with pKa of 2 approximately (measured 
by one of my colleague, Parsons, Z.D.). The buffers that we used for IC50 assay was neutral 
(pH 7), that meant more than 99% of TDZ was negatively charged in the condition and 
bound to PTP1B active site pocket with charge-charge interaction.  Therefore, IC50 of 17b 
and 19b in higher ionic strength buffer (ionic strengthHigh-Salt= 0.580 M) was greater than 
that in low ionic strength buffer (ionic strengthLow-Salt= 0.0144 M). This observation was 
corresponding to the salt effect study by Zhang and team in 2001.15 In their study, the 
most potent PTP1B inhibitor, DFMP 1, was synthesized and the affinity of the inhibitor, 
reported as Ki (dissociation constant), in different buffers with different ionic strengths 
was investigated. Due to the highly ionic property (five negatively charged at pH 7), this 
compound was susceptible to changes in ionic strength. Increasing ionic strength from 25 
mM to 42.5 mM and 0.15 M, the charged-charged interaction was weakened and IC50 
increased from 0.14 nM to 0.69 nM and 2.4 nM, respectively.15 
DMSO could also potentially influence IC50. We observed that higher amount of 
DMSO in pNPP assay increased IC50 up to 10-fold. The explanation of the DMSO effect on 
protein-ligand was still unknown because there were few attentions on the effect to date. 
However, this observation was complementary to the very recent work by Cubrilovic and 
Zenobi.16 Studied by nano ESI-MS, Kd (dissociation constant) of three different protein-
ligand systems were determined. They found that varying proportion of DMSO as a co-
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solvent from 0% to 8% in a buffer increased Kd value up to 10-fold in the case of tight 
binding carbonic anhydrase-chlorothiazide. However, the causes of this solvent effect 
remained unclear. 
In 2006, Shoichet reported interpretation of steep does-response curves, defined 
by Hill’s coefficient of above 1.5.17 According to the study, the steepness of the curves 
suggested three mechanism, i.e. multi-site binding, inhibitor phase transition, and 
stoichiometric inhibition caused by a high enzyme to Kd ratio. The first mechanism is a 
result of several inhibitor molecules binding to one enzyme molecule. The slope of the 
dose-response curve becomes steeper (higher Hill’s coefficient) as the number of binding 
site increases. The second mechanism could be observed when the inhibitors undergoing 
physical phase transition (precipitation or colloid formation) as increasing its 
concentration. If the phase transition associated with its target inhibition, a steep dose-
response curve was observed. Finally, the steep dose-response curves would also take 
place if the enzyme concentration exceeded the Kd value of the inhibitor (usually in the 
case of high affinity inhibitor) and inhibition in this manner would be stoichiometric. In 
addition to the second mechanism, Coan and team18 studied the inhibitory mechanism of 
some compounds that could aggregate, so called “aggregate-based inhibitor” as its 
concentration was increased. The study showed that the aggregation inhibited its target 
by unfolding enzyme molecules and that could lead to false positives in IC50 
interpretation. Regarding the Hill’s coefficients of 19a, 20, and 21 of 1.70, 2.50, and 1.60, 
respectively (Figure 2.8a, b, c), these exo-affinity labeling agents could be aggregate-
based inhibitor. To identify the inhibitor type, further investigation are needed. 
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2.6) Kinetics of the Inactivation of PTP1B by Thioester TDZ 
 
Stated above, our E-L-pYi are designed to bind to PTP1B in two steps, non-covalent 
interaction and covalent modification. The non-covalent interactions, such as hydrogen 
bonds, charge-charge interactions, hydrophobic interactions, and etc., occur when TDZ 
reversibly binds to PTP1B by the rate constant k1, rapidly forming an enzyme-inactivator 
(𝐸 ∙ 𝐼) complex (scheme 2.1). Simultaneously, some of 𝐸 ∙ 𝐼 complex can collapse and 
become free enzyme molecules and free inactivator molecules with the rate constant k-1. 
As a result, an equilibrium is established by a dissociation equilibrium constant KI, defined 
by k-1/k1. Therefore, KI reflects the affinity of the inactivators to the enzyme. The lower KI 
value, the relatively larger k1 comparing to k-1, and the inactivators bind to the target more 
tightly. Note that this is only true if kinact is slower relative to k1 and k-1. The second step is 
covalent modification of an electrophile moiety of E-L-pYi to a nucleophilic residue on 
PTP1B. This chemical step occurs by first-order rate constant kinact, represented by 
𝑘𝑖𝑛𝑎𝑐𝑡 × [𝐸 ∙ 𝐼] (scheme 2.1). Thus, a high affinity (low KI value) inactivator gives high 
concentration of 𝐸 ∙ 𝐼 complex and enhanced observed rate of inactivation. Note that this 
is not the case at high concentration of E-L-pYi (discussed below) and/or when the 
concentration of the inactivator exceeding solubility limit. Due to this irreversible 
attachment, an E-L-pYi interacts with PTP1B in time-dependent manner and the reaction 
proceeds to completion rather than equilibrium.19 
To determine the kinetic constants KI and kinact, we utilized conventional pNPP 
assays to follow decrease of PTP1B activity over time course of the inactivation process 
at different E-L-pYi concentrations. The observed rate constant of inactivation (kobs) at 
37 
 
each concentration was determined from slope of semi-logarithmic plot of enzyme 
activity against time (Figure 2.9a). Then, the kobs values are re-plotted against E-L-pYi 
concentration (Figure 2.9b) and fitted data to a hyperbolic equation (Scheme 2.6).19  KI 
was obtained as the concentration that gives half kobs and kinact was obtained as maximum 
kobs. 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 a) A semi-logarithmic of %enzyme activity against time plot for each concentration of an exo-
affinity labeling agent (E-L-pYi). b) Re-plot kobs (slope from a)) vs concentration of the exo-affinity labeling 
agent and fit the data to the hyperbolic equation (Scheme 2.6). KI was obtained as the concentration that 
gives half kobs and kinact was obtained as the maximum kobs, respectively. 
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𝑘𝑜𝑏𝑠 =
𝑘𝑖𝑛𝑎𝑐𝑡
1 +
𝐾𝐼
[𝐼]
 
 
Scheme 2.6 A hyperbolic equation to obtain values of KI and kinact. where kobs= observed 1st-order rate of 
inactivation, kinact= 1st-order rate of inactivation, KI=dissociation constant, [I] = concentration of an 
inactivator. 
 
 
Regarding scheme 2.1, the rate of covalent formation/inactivation is directly 
proportional to the concentration of 𝐸 ∙ 𝐼 complex, represented by 𝑘𝑖𝑛𝑎𝑐𝑡 × [𝐸 ∙ 𝐼]. 
Increasing concentration of the inactivator drives the equilibrium forward, more 𝐸 ∙ 𝐼 
complex is formed, and subsequently the rate of inactivation becomes faster. However, 
this is the case only at low concentration of the exo-affinity labeling agent. At high 
concentration, the enzyme becomes saturated by the labeling agent molecules. In other 
words, all PTP1B active sites were occupied by the inactivator, there was no further 𝐸 ∙ 𝐼 
complex can be formed. At this point, the rate of inactivation was at maximum and 
independent on the inactivator concentration resulting in plateau in the kobs-
concentration plot. (Figure 2.9b)  
Among exo-affinity labeling agents that we synthesized, 19a, 20, and 21 were 
subjected to inactivation assays against PTP1B. 19a was expected to be the most 
susceptible to nucleophilic attack and has relatively high kinact since pKa of an aryl thioester 
(pKa ~ 7) was lower than those of an alkyl thioester (pKa ~ 10) and an aryl amine (pKa ~ 
30). On the other hand, the aryl amine analogue 21 should be inert toward a nucleophile 
on PTP1B and kobs would be zero. Additionally, these three molecules were expected to 
bind to the enzyme with the relatively similar affinity (similar KI values) because they all 
possessed the same TDZ moiety which interacts with the enzyme with the same binding 
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mode. (Figure 2.10a) Furthermore , as mentioned earlier, DMSO was presumed to have 
negative influence on the inactivation process, according to study by Cubrilovic and 
Zenobi.16 Therefore, high concentration of DMSO could weaken the interaction between 
the exo-affinity labeling and the enzyme, lowering the concentration of 𝐸 ∙ 𝐼 complex, and 
could decrease the rate of inactivation. In this thesis, 19a was subjected to assays in 5% 
and 20% DMSO, expecting that the compound in 20% DMSO exhibited slower inactivation 
rate (smaller kinact value) and bind to PTP1B more weakly (larger KI value) than the 
compound does in 5%DMSO. (Figure 2.10a) 
a) 
 
 
 
 
 
 
b)  
 
 
 
 
 
Figure 2.10 Plot kobs vs concentration of 19a, 20, and 21 in 5%DMSO and 20%DMSO a) mock data b) 
observed data (n≥3). 
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Figure 2.11 Plot ln (%Activity) vs time of a) 19a (5%DMSO), b) 19a (20%DMSO), c) 20 (5%DMSO) and d) 21 
(5%DMSO) (n≥3). 
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c)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12 Plot kobs vs concentration of 19a, 20, and 21. a) 19a (5%DMSO), b) 19a (20%DMSO), c) 20 
(5%DMSO) and d) 21 (5%DMSO) (n≥3). 
 
Interestingly, the observed data was different from the expectation (Figure 2.10b). 
First of all, kobs vs concentration plots of 19a and 20 were not fit the hyperbolic equation 
(Figure 2.12a, b). At low concentration (0-100 µM), kobs increased very slowly, but 
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concentration (300-500 µM). The plateau occurred presumably because all PTP1B active 
sites were occupied at this concentration range and no faster rate of inactivation could 
be achieved. The unexpected plots might suggest that the molecules inhibited or 
inactivated the enzyme with different mechanism from a typical exo-affinity labeling 
agents. Second, the amide analog 21 did not inactivate PTP1B as expected, since kobs 
remained relatively unchanged as increasing concentration (Figure 2.12d, Figure 2.13d). 
This data possibly showed that the amide bond could tolerate nucleophilic attack by a 
reactive residue on the enzyme. Third, 19a in 20%DMSO seemed to bind to PTP1B more 
loosely and inactivated the enzyme as quickly as in 5%DMSO. Forth, the benzyl TDZ analog 
20 in 5% DMSO was likely to bind to PTP1B relatively more tightly (lower KI) and inactivate 
the enzyme with relatively similar rate (similar kinact) than 19a in 5% DMSO, although 20 
was expected to possess similar affinity and lower inactivation rate than those of 19a. 
An alternative hypothesis is that these three compounds were aggregate-based 
inhibitor. Based on studies by Shoichet17 mentioned earlier, the Hill’s coefficient from 
dose-response curves of 19a and 20 were more than 1.5 which was considered steep. 
One possible inactivation mechanism of compounds that showed steep dose-response 
curves was that the compounds at a certain concentration range aggregated and the 
aggregation associated to enzyme inhibition, according to study by Coan.18 Surprisingly, 
some of our data supported this hypothesis. Firstly, re-plotting kobs vs low concentrations 
of 19a (below 100 µM) fitted the hyperbolic equation in Scheme 2.6, with R2 value of 
0.986845194, but deviated at concentration above 100 µM, with R2 of 0.611790504 
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(Figure 2.13a). This could suggest that the compound behaved like a typical inactivator at 
concentrations below 100 µM and aggregated at concentrations above 100 µM. 
a) 
 
 
 
 
 
 
 
 
b)  
 
 
 
 
 
 
Figure 2.13 a) Plot kobs vs concentration of 19a in 5% DMSO (n=1); Fitting kobs values of 10, 50, 75, and 100 
µM to the hyperbolic equation gave R2 of 0.986845194. However, fitting all kobs values to the equation gave 
R2 of 0.611790504. b) Plot kobs vs concentration of 21 in 5% DMSO (n=3) showed that kobs values of the 
concentrations above 500 µM > 0 s-1. 
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Secondly, kobs values of Me/Ph Amide TDZ 21 increased at concentration above 
500 µM (Figure 2.13b). Ideally, 21 was not expected to inactivate the enzyme due to high 
pKa of the amide group, thus kobs should be 0 s-1 at all compound concentrations. 
However, the compound showed enzyme inactivation at high concentration. This also 
could suggest that the compound aggregated and the resulting aggregates associate with 
inhibition of PTP1B activity. 
 
2.7) Conclusion 
Based on our data, we developed Me/Ph Thioester TDZ 19a, Me/Bn Thioester TDZ 
20, and Me/Ph Amide TDZ 21 which could be potential exo-affinity labeling agents 
targeting PTP1B. The design of these molecules were composed of three parts; an 
electrophile (E), a linker (L), and a phosphotyrosine isostere (pYi), E-L-pYi. Thioesters 
(phenyl analog 19a and benzyl analog 20) were chosen as the electrophiles as they were 
susceptible to nucleophilic attack according to literatures. The linker was several C-C 
bonds long connecting the electrophile part with pYi. Lastly, TDZ as pYi moiety was 
included in our compounds due to mode of binding and cell permeability reason. The 
compounds were designed to interact with a few amino acids in PTP1B active site using 
TDZ moiety and subsequently to modify a nucleophilic residue proximal to the active site 
pocket via an electrophilic counterpart forming a covalent bond. Further study was 
needed to identify the target residue. Moreover, the affinity of our E-L-pYis were reported 
as IC50 values and estimated KI values (table 2.1). High concentration of salt and DMSO 
seemed to have negative effect on enzyme-inactivator binding resulting in increased IC50. 
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Inactivation kinetics of the three compounds were also investigated. 19a and 20 
interacted with PTP1B in time-dependent manner, suggesting that the compounds 
possibly inactivated the enzyme target rather than inhibited which was time-
independent. Unlikely, the amide analogue 21 as expected interacted with the enzyme in 
time-independent manner which suggested that the compound was not capable of 
forming the covalent bond and therefore inhibited the target enzyme rather than 
inactivated. However, several evidence suggested that these compounds could be 
aggregate-based inhibitor at high concentration. Nonetheless, further investigation was 
necessary to identify the mechanism of inactivation. 
 
 
 
2.8) Material and Method 
 
Chemicals and Reagents Reagents were purchased from the following suppliers: 
5-bromo-2-methyl aniline, 5-bromo-2-methoxy aniline, methyl bromoactate, 
ethyldiisopropylamine, triethylamine, dimethyl formamide, chlorosulfonyl isocyanate, 
dichloromethane, triethyl amine, trifluoroacetic acid, sodium hydride, 1,2-
dimethoxyethane, bis(trisphenyl phosphine)palladium (II) dichloride, thiophenol, benzyl 
mercaptane, alanine, (benzotriazol-1-yloxy) tris(dimethylamino)phosphate (BOP), 
tris(hydroxymethyl)aminomethane (Tris), 2-[bis-(2-hydroxyethyl)-amino]-2-
hydroxymethyl-propane-1,3-diol (Bis-tris), 4-nitrophenyl phosphate disodium salt 
hexahydrate (pNPP), DL-dithiothreitol (DTT), diethylenediamine tetraacetic acid disodium 
(EDTA), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 
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diethylenetriaminepentaacetic acid (DTPA), sodium hydroxide, and sodium acetate 
(99+%) were obtained from Sigma-Aldrich. potassium carbonate and sodium chloride 
were purchased from Fischer Chemical. 4-carboxybenzene boronic acid was obtained 
from Boron Molecular. Zeba mini centrifugal buffer exchange column was purchased 
from Thermoscientific, and Tween-80 were purchased from Pierce Biotechnology. 
Amicon Ultra centrifugal filter devices were purchased from Millipore. The enzyme 
consisting of amino acids 1-322 of human PTP1B was expressed and purified as described 
previously20 and the concentration of active enzyme in stock solutions was determined as 
described by Pregel21 et. al. Thiol-free  PTP1B was prepared by a Zeba mini centrifugal 
desalting column buffer exchange column according to manufacturer protocol. The buffer 
exchange columns were equilibrated before use in sodium acetate (100 mM), Tris (50 
mM), Bis-tris (50 mM, pH 7), DTPA (10 mM), and Tween 80 (0.05%). The thiol-free enzyme 
was further diluted, if necessary, with sodium acetate (100 mM), Tris (50 mM), Bis-tris (50 
mM, pH 7), DTPA (10 mM), and Tween 80 (0.05%). NMR spectra were recorded using 
Bruker DRX 500 or DRX 300 MHz instruments at University of Missouri-Columbia. HRMS 
data were recorded on LC/ESI TOF mass spectrometer by Mass Spectrometry Laboratory, 
University of Illinois at Urbana-Champaign. MS data of 16a was recorded on direct 
infusion ESI/APCI mass spectrometer, University of Missouri-Columbia. IR experiments 
were recorded on a Perkin-Elmer Spectrum 100 FT-IR spectrometer. 
Expression and Purification of PTP1B (1-298 domain) The enzyme was prepared 
by Lewis, S.M., my colleague, using a protocol reported by Zhou22 et. al. The PTP1B (1-
298) plasmid was transformed into E. coli BL21AI cells and plated on LB Agar containing 
48 
 
ampicillin (50 μg/mL). The plate was incubated at 37 oC overnight and a single colony of 
the transformant was picked to inoculate 10 mL starter culture made of 1% tryptone and 
0.5% yeast extract. This was incubated at 37 oC with constant shaking at 250 rpm, 
overnight. The starter culture was used to inoculate 1 L of auto-induction media,23 and 
the cells were allowed to shake constantly for two hours at 37 oC and 250 rpm. After two 
hours of cell growth, the temperature was reduced to 25 oC, and 0.2% arabinose was 
added to the media. Cells were harvested after 20-21 hours by centrifugation at 4 oC and 
3500 rpm and resuspended in Buffer A (20 mM Tris, 150 mM NaCl, 10% glycerol pH 7.5). 
The cell pellet was quick-frozen into liquid nitrogen for later use. Frozen cells were thawed 
at 4 oC in the presence of the following protease inhibitors: 10 µM leupeptin, 1 µM 
pepstatin A, 1 mM PMSF. Cells were stirred for 15-20 minutes at 4 oC followed by 
disruption using sonication. Unbroken cells and debris were removed by centrifugation 
for 60 min at 17,000 rpm. The supernatant was collected and subjected to a second 
centrifugation step for 30 min at 17,000 rpm. The resulting supernatant was used for 
further purification by immobilized metal-ion affinity chromatography (Ni2+-charged 
HiTRAP; GE Healthcare). The fractions were eluted using buffer B (Buffer A supplemented 
with 1 M imidazole). Fractions containing PTP1B were pooled and mixed with TEVP (1 mg 
of TEVP per 40 mg of PTP1B) and 1 mM THP. The sample was incubated for 8 h at 20 oC 
and then dialyzed against buffer A. The dialyzed protein was again loaded onto the Ni2+ 
charged column using buffer A. Tag-free PTP1B was collected in both the flow-through 
and by elution in 3% buffer B. The purified protein was dialyzed into 10 mM Tris, 25 mM 
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NaCl, 1 mM EDTA, 1 mM THP pH 7.5. Finally, the protein was distributed into thin-walled 
PCR tubes, quickfrozen in liquid nitrogen, and stored at –80 oC. 
IC50 Determination Free thiols were removed from stock solutions of purified 
PTP1B using Zeba mini centrifugal exchange columns according to the manufacturer’s 
protocol. The exchange buffer contained 50 mM Bis-Tris, 2mM EDTA and 0.05% Tween 
80 at pH 7.0. PTP1B was adding to an assay mixture pNPP, different concentrations of 
compounds (19a, 20, or 21), 4% or 20%DMSO in a buffer (50 mM Bis–Tris, 2 mM EDTA, 5 
mM DTT, 0.05% Tween80) to achieve a final PTP1B concentration of 48 nM, 60 nM, or 72 
nM and a final pNPP concentration of 2 mM or 0.4 mM. Absorbance at 410 nm of the 
mixture was measured every 5 s for 1 min. Activity of PTP1B in the presence of each 
compound concentration was a slope of a plot of absorbance (410 nm) against time (s). 
The activities relative to the uninhibited activity were used to calculate the relative 
activity which were re-plotted against the compound concentrations. IC50 was the 
concentration that gave 50% PTP1B relative activity. 
Time-Dependent Inactivation of PTP1B Free thiols were removed from a stock 
solution of concentrated PTP1B by gel filtration/buffer exchange into buffer A (50 mM 
Bis-Tris, 50 mM Tris, 1.0 mM DTPA, 100 mM NaOAc, and 0.05% Tween 80 at pH 7.0) or 
buffer B (50 mM Bis-Tris, 2mM EDTA and 0.05% Tween 80 at pH 7.0) using a Zeba mini 
centrifugal desalting column. Upon inactivation process, 10 µL of concentrated PTP1B 
stock was added into a 90 µL inactivation mixture (various concentration of 19a, 20, or 
21, DMSO, DTT, buffer A or buffer B) at 25 oC to the final concentration of 0.8 µM, 5% or 
20% DMSO, and 100 µM DTT. A 10 µL aliquot of the inactivation mixture was removed 
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every 30 min and placed into 490 µL in an activity assay buffer (50 mM Bis-Tris, 100 mM 
NaCl, 10 mM DTPA, and 20 mM pNPP pH 6.0) at 30°C and incubated for additional 10 
minutes (Final concentration of 8 nM PTP1B). The enzymatic reaction was quenched with 
the addition of 500 µL 2M NaOH. The amount of p-nitro phenolate released during the 
reaction was determined by UV-vis measurement of the absorbance at 25°C and 410 nm. 
 
2.9) Synthesis 
Methyl N-(4-bromo-2-methylphenyl) amino acetate (13a) To a 
stirred solution of 5-bromo-2-methylaniline (5.0 g, 27 mmol) in 
DMF (6 mL) was added methyl bromoacetate (2.4  mL, 26 mmol) 
and diisopropylethylamine (23.6 mL, 136 mmol). The reaction mixture was stirred for 18 
h at 60 oC and cooled down to room temperature. The solution was poured in cold ice 
water and refrigerated for 1.5 h. The precipitate was filtered, washed with cold water, 
and dried in vacuo to obtain an off-white solid. If necessary, the title compound was 
purified by column chromatography (10% EtOAc/Hexane) on silica gel to obtain 13a (6.5 
g, 93%) as a white solid (mp 71-73 oC). Rf (10% EtOAc/Hexane) 0.32. 1H-NMR (500 MHz, 
CDCl3): δ 6.90 (1H, d, J = 2.1 Hz), 6.72 (1H, dd, J = 8, 2Hz), 6.53 (1H, d, J = 2 Hz), 3.97 (2H, 
s), 3.06 (3H, s), 2.12 (3H, s). 13C-NMR (500 MHz, CDCl3): δ 173.59, 148.49, 132.33, 122.77, 
121.33, 120.81, 113.29, 52.58, 45.93, 17.15. HRMS (ESI-TOF): m/z calcd for C10H13NO2Br 
258.0130 [M+ + H]; Found 258.0131. IR (neat): 3416, 3003, 2957, 1750, 1222 cm-1. 
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Methyl 2-((5-bromo-2-methylphenyl) (N-(tert-
butoxycarbonyl) sulfonyl) amino) acetate (14a)  To a 
stirred solution of chlorosulfonyl isocyanate (2.81 mL, 
32.1 mmol) in dry DCM (50.0 mL) was cooled to 0 oC, slowly added t-BuOH (3.34 mL, 35.1 
mmol). The solution mixture was stirred for 15 min at room temperature to obtain t-
butylchlorosulfony carbamate solution and used without purification. 
To a solution of 13a (0.51 g, 1.9 mmol) in DCM (10.0 mL) was cooled to 0 oC and 
added the solution of t-butylchlorosulfonyl carbamate, followed by addition of 
Triethylamine (0.81 mL, 5.8 mmol). The reaction solution, then, was warmed to room 
temperature and stirred for 2 h. After stirring, the solution was washed with Three times 
with H20 (10.0 mL). The organic layer was dried over Na2SO4, filtered, concentrated by 
rotary evaporation, and purified by column chromatography (10%EtOAc:Hexane) on silica 
gel to give 14a (0.86 g, 34%) as a white solid (mp 131-132 oC). Rf (10% EtOAc/Hexane) 
0.17.1H-NMR (300 MHz, CDCl3): δ 7.61 (1H, d, J = 2.1 Hz), 7.39 (1H, dd, J = 8.4, 2Hz), 7.16 
(1H, d, J = 8.4 Hz), 4.56 (2H, s), 3.74 (3H, s), 2.42 (3H, s), 1.53 (9H, s). 13C-NMR (500 MHz, 
CDCl3): δ 169.53, 149.94, 149.21, 139.21, 138.40, 133.10, 132.61, 132.53, 119.40, 84.18, 
77.41, 77.16, 76.90, 55.06, 52.56, 28.13, 17.80. HRMS (ESI-TOF): m/z calcd for 
C15H21N2O6BrNa 459.0201 [M+ + Na]; Found 459.0206. IR (neat): 3249, 2982, 1734, 1368, 
1150, 1139 cm-1.  
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Methyl 2-((5-bromo-2-methylphenyl) (sulfonyl) amino) acetate 
(15a) To a stirred solution of 14a in (3.4 g, 7.7 mmol) was slowly 
added TFA (5.9 mL, 77 mmol) under N2 atmosphere. The reaction 
solution was stirred for 3h at room temperature. Monitoring the progress of the reaction 
by TLC (EtOAc:Hexane)stained with ninhydrin, more TFA was added if necessary. The 
solvent was evaporated in vacuo and azeotroped with toluene to remove trace TFA and 
dried overnight to obtain 15a (1.8 g, 70%) as a brown oil (mp 112-114 oC). 1H-NMR (500 
MHz, CDCl3): δ 7.72 (1H, D, J = 0.9HZ), 7.40 (1H, DD, J = 4.8, 1.2HZ), 7.18 (1H, d, J = 4.8 Hz), 
5.26 (2H, s), 3.78 (3H, s), 2.33 (3H, s). 13C-NMR (500 MHz, CDCl3): δ 171.79, 140.31, 138.52, 
133.10, 132.51, 131.98, 119.44, 77.41, 77.16, 76.90, 54.45, 52.91, 17.92. HRMS (ESI-TOF): 
m/z calcd for C10H14N2O4SBr 336.9858 [M+ + H]; Found 336.9858. IR (neat): 3381, 3279, 
2955, 1739, 1358 cm-1.  
 
5-(2-methyl-4-bromophenyl)-1,2,5-thiadiazolidin-3-one-1,1-
dioxide (16a) To a solution of 15a (1.13 g, 0.263 mmol) in anhydrous 
THF (5.0 mL) was purged with N2. In a separate flask, NaH (60% 
dispersion in mineral oil) (0.263 g, 10.9 mmol) was dissolved in anhydrous THF (2.0 mL) 
and purged with N2. The suspension of NaH/THF was slowly added to the solution of 15a 
under N2 and the reaction mixture was stirred for 1 h at room temperature. The reaction 
mixture was quenched via slow addition of H2O (2.0 mL), basified with 10%NaOH (pH~14), 
and EtOAc (10.0 mL) was added. The aqueous layer was washed three times with Hexane 
(10.0 mL) to remove mineral oil, maintaining pH~14 to prevent product loss. The aqueous 
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layer was separated and acidified (pH~1) with 10% HCl, and extracted three times with 
EtOAc (10.0 mL), dried over Na2SO4, concentrated by rotary evaporator, and purified by 
column chromatography (10% EtOAc:PET Ether) on silica gel to give 16a (0.73 g, 65%) as 
an off-white solid (mp 196-198 oC). Rf (10% EtOAc/PE) 0.22. 1H-NMR (300 MHz, (CD3)2CO): 
δ 7.69 (1H, d, J = 2.1Hz), 7.48 (1H, dd, J = 8.1, 2.1Hz), 7.27 (1H, d, J = 8.1 Hz), 4.48 (2H, s), 
2.38 (3H, s). 13C-NMR (500 MHz, (CD3)2CO): δ 166.33, 139.98, 136.20, 133.79, 133.30. 
119.87, 57.45, 17.77. MS (ESI-APCI): m/z calcd for C9H9N2O3SBr 302.94 [M+ - H]; Found 
303.24. IR (neat): 3422, 1739, 1326, 1169 cm-1.  
  
5-(2-methyl-4-(4-carboxyphenyl) phenyl)-1, 2, 5-
thiadiazolidin-3-one-1, 1-dioxide (18a) To a solution of 
16a (1.0 g, 3.3 mmol, 1g), K2CO3 (1.8 g, 13 mmol) and 4-
carboxyphenylboronic acid (0.82 g, 4.9 mmol) in 3:1 DME/H2O (40.0 mL) in a seal tube 
was degassed for 10-15 min at room temperature. The mixture was added 5 mol% of 
Pd(PPh3)2Cl2 (0.12 g, 0.16 mmol) and degassed for another 10-15 min. The reaction 
mixture was stirred for 10 h at 100 oC, monitoring the progress of reaction by TLC (10% 
AcOH:EtOAc). The used Pd catalyst and solid impurities were filtered and the filtrate was 
concentrated by rotary evaporation. The basic residue was washed with three times with 
EtOAc (30.0 mL), acidified with conc. HCl (pH~1), extracted three times with EtOAc (30.0 
mL), dried over Na2SO4, and filtered. The final filtrate was concentrated by rotary 
evaporation and purified by column chromatography (gradient elution 10-100% 
EtOAc:Hexane + 5%AcOH) on silica gel to obtain 18a (0.49 g, 43%) as a brown solid 
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(decomposed 223-225 oC). Rf (10% AcOH:EtOAc) 0.2. 1H-NMR (500 MHz, (CD3)2CO): δ 
8.10 (2H, d, J = 8.5Hz), 7.85 (1H, d, J = 2Hz), 7.76 (2H, d, J = 8.5Hz), 7.68 (1H, dd, J = 8, 2Hz), 
7.47 (1H, d, J = 8Hz), 4.55 (2H, s), 2.49 (3H, s). 13C-NMR (500 MHz, (CD3)2CO): δ175.20, 
169.61, 145.56, 140.63, 140.47, 136.17, 133.02, 131.42, 130.89, 128.90, 128.83, 127.87, 
58.46, 18.00. HRMS (ESI-TOF): m/z calcd for C16H14N2O5NaS 369.0521 [M+ + Na]; Found 
369.0537. IR (neat): 3586, 3004, 2922, 1715, 1419, 1363, 1222 cm-1. 
 
5-(2-methyl-4-(4-(S-phenylthiocarbonyl) phenyl) 
phenyl) -1, 2, 5-thiadiazolidin-3-one-1, 1-dioxide 
(19a) To a solution of 18a in (53.3 mg, 0.154 mmol) 
and BOP (136 mg, 0.308 mmol) in dry DMF (5.0 mL) was degassed and added 
diisopropylethylamine (0.14 mL, 0.77 mmol). The solution mixture was stirred for 15 min 
at room temperature, followed by addition of thiophenol (0.029 mL, 0.31 mmol). The 
reaction solution was stirred for 1-2 hr at room temperature, monitoring by TLC 
(10%AcOH/EtOAc). DMF was removed in vacuo, the resulting residue was added EtOAc 
(5 mL), and washed three to five times with water (5 mL). The organic layer was 
concentrated by rotary evaporation and purified by column chromatography (gradient 
elution from 10-100% EtOAc:Hexane + 5%AcOH) on silica gel to obtain 18a (57.4 mg, 85%) 
as a white solid (decomposed 146-148 oC). Rf (10% AcOH/EtOAc) 0.32. 1H-NMR (500 MHz, 
(CD3)2CO): δ 8.10 (2H, d, J = 8.5Hz), 7.86 (1H, d, J = 2Hz), 7.82 (2H, d, J = 8.5Hz), 7.64 (1H, 
dd, J = 8, 2Hz), 7.54-7.48 (5H, m), 7.44 (1H, d, J = 8Hz), 4.38 (s, 1H), 2.49 (3H, s). 13C-NMR 
(500 MHz, (CD3)2CO): δ 190.97, 174.81, 146.79, 140.84, 139.79, 137.69, 136.68, 136.29, 
55 
 
132.92, 130.65, 130.33, 129.08, 128.74, 128.70, 128.30, 128.17, 59.80, 18.16. HRMS (ESI-
TOF): m/z calcd for C22H19N2O4S2 439.0786 [M+ + H]; Found 439.0792. IR (neat): 3445, 
3059, 2959, 2959, 1734, 1700 cm-1. 
 
5-(2-methyl-4-(4-(S-benzylthiocarbonyl) phenyl) 
phenyl)-1, 2, 5-thiadiazolidin-3-one-1, 1-dioxide 
(20) The title compound was prepared in the 
same manner as compound 19a, benzylmercaptane (0.037 mL, 0.28 mmol) was used 
instead of thiophenol to synthesize 20 (50.1 mg, 77%) as a white solid (decomposed 85-
87 oC). Rf (10% AcOH/EtOAc) 0.32. 1H-NMR (500 MHz, (CD3)2CO): δ 8.02 (2H, d, J = 8Hz), 
7.99 (1H, d, J = 1.5Hz), 7.84 (2H, d, J = 8.5Hz), 7.67 (1H, d, J = 6.5Hz), 7.46-7.43 (3H, m), 
7.34 (2H, t, J = 7.5Hz), 7.26 (1H, t, J = 7.5Hz), 4.58 (2H,s), 4.37 (2H,s), 2.49 (3H, s). 13C-NMR 
(500 MHz, (CD3)2CO): δ 190.74, 166.08, 145.45, 140.72, 139.54, 138.80, 136.62, 135.34, 
132.93, 129.83, 129.44, 128.97, 128.86, 128.60, 128.10, 128.06, 57.57, 17.94. HRMS (ESI-
TOF): m/z calcd for C23H21N2O4S2 453.0943 [M+ + H]; Found 453.0941. IR (neat): 3442, 
3026, 2952, 1734, 1652 cm-1. 
 
5-(2-methyl-4-(4-(S-phenylaminocarbonyl) phenyl) 
phenyl)-1, 2, 5-thiadiazolidin-3-one-1, 1-dioxide 
(21) The title compound was prepared in the same 
manner as compound 19a, aniline (0.027 mL, 0.29 mmol) was used instead of thiophenol 
to give 21 (33.5 mg, 54%) as a white solid (decomposed 48-49 oC). Rf (10% AcOH/EtOAc) 
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0.32. 1H-NMR (500MHz, (CD3)2CO): δ 8.02 (2H, d, J = 8Hz), 7.85 (1H, s), 7.79 (2H, d, J = 
8Hz), 7.71 (2H, d, J = 7.5Hz), 7.64 (1H, d, J = 8Hz), 7.44 (1H, d, J = 7.5Hz), 7.37 (3H, t, J = 
7.5Hz), 7.16 (3H, t, J = 7.5Hz), 4.43 (2H,s), 2.48 (3H, s). 13C-NMR (500 MHz, (CD3)2CO): δ 
168.51 (presumably two carbonyl carbons have equivalent chemical shift), 144.63, 
140.44, 140.32, 139.90, 137.01, 135.10, 132.93, 129.81, 129.33, 128.73, 128.40, 127.96, 
125.62, 122.36, 59.81, 18.07. HRMS (ESI-TOF): m/z calcd for C22H20N3O4S 422.1175 [M+ + 
H]; Found 422.1174. IR (neat): 3392, 3955, 2956, 1734, 1652 cm-1. 
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Figure 2.14 IC50 of 8 in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
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Figure 2.15 IC50 of 19b in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
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Figure 2.16 IC50 of 17 in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
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Figure 2.17 IC50 of 19a in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
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Figure 2.18 IC50 of 20 in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
 
0
10
20
30
40
50
60
70
80
90
100
110
0 0.5 1 1.5 2 2.5 3
%
A
ct
iv
it
y
log [Me/Bn Thioester TDZ] µM 
IC50 Me/Bn Thioester TDZ 20 >300 µM  (1 experiments)
(20%DMSO, High Salt, 2 mM pNPP, 24 nM PTP1B, r.t.)
0
10
20
30
40
50
60
70
80
90
100
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
%
A
ct
iv
it
y
log [Me/Bn Thioester TZD] µM
IC50 Me/Bn Thioester TZD 20 = 631.0 µM (1 experiments)
(20%DMSO, Low Salt, 0.4 mM pNPP, 24 nM PTP1B, r.t.)
Hill's coefficient = 1.14
0
10
20
30
40
50
60
70
80
90
100
110
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
%
A
ct
iv
it
y
log [Me/Bn Thioester] µM
IC50 Me/Bn Thioester 20 = 270.2±36.1 µM (7 experiments)
(4%DMSO, Low Salt, 0.4 mM pNPP, 72nM PTP1B, r.t.)
64 
 
a) 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
c) 
 
 
 
 
 
 
 
 
Figure 2.19 IC50 of 21 in a) 20%DMSO-high salt, b) 20%DMSO-low salt, and c) 4%DMSO-low salt. 
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